Shanghai Henlius Biotech
3 clinical trials · 3 recruiting · INDUSTRY
Trials by Shanghai Henlius Biotech
RECRUITINGPhase 2 / Phase 3NCT07294508
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic...
Sponsor: Shanghai Henlius BiotechEnrolling: 7061 location
HER2 + Breast Cancer
RECRUITINGPhase 2NCT06349980
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or...
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of Serplulimab Injection (HLX10, a Recombinant Anti-PD-1...
Sponsor: Shanghai Henlius BiotechEnrolling: 1171 location
Carcinoma, Hepatocellular
RECRUITINGPhase 2NCT06769113
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to...
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic...
Sponsor: Shanghai Henlius BiotechEnrolling: 721 location
Esophageal Cancer